Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
Losing fat while preserving lean mass is very different from simply losing weight
Pharmaceutical companies are intensifying R&D investments to optimize oral GLP-1 efficacy and expand indication approvals
Weight loss: GLP-1s like Tirzepatide are also approved for weight loss in individuals without diabetes
However, despite significant weight loss, liraglutide-treated animals displayed increased bone mass, trabecular number, and cortical thickness in the appendicular and axial skeletons, with marked improvement in bone formation parameters [5557]
Correlate your sleep data with injection timing, meal timing, exercise timing, and dose changes